RG-6333
Based on 1 Customer Validation
RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001).
For research use only. We do not sell to patients.
- Purity: 98.05%
- Molecular Weight:145.98 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
CD19 & CD28
RG-6333 (RO 7443904) has a lower affinity for CD28 in CHO cells (Kd: 36 nM), binding weakly but sufficient to provide a co-stimulatory signal[1].
RG-6333 is inactive as a single agent in human peripheral blood mononuclear cells (PBMC) and activates T cells only upon engagement of the T cell receptor (TCR)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
RG-6333 (1 mg/kg, i.v. one dose) significantly inhibits tumor growth in humanized NSG mice bearing subcutaneous NALM-6 lymphoma in combination with Glofitamab (HY-P99024) (0.15 mg/kg), and increases tumor-infiltrating CD8+ T cells[1].
RG-6333 (1 mg/kg, i.v. one dose) combines with Glofitamab (0.15 mg/kg) in an aggressive in vivo lymphoma (DLBCL WSU-DLCL2-Fluc) humanized mice model results in complete tumor regression, with an initial transient weight loss due to T cell activation, but subsequent recovery[1][2].
RG-6333 (1 mg/kg, i.v. one dose) combines with glofitamab (0.15 mg/kg) in a humanized NSG mice model bearing subcutaneous OCI-Ly18 tumors increases pro-inflammatory T cell signatures in tumors and promotes transendothelial migration, and triple combination with CD19–4-1BBL deepens and prolongs anti-tumor responses in vivo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Humanized NSG mice bearing orthotopic WSU-DLCL2-Fluc tumors[1]
-
Dosage:1 mg/kg
-
Administration:i.v. three times combined injection
-
Result:Combined with Glofitamab (0.15 mg/kg) achieved complete tumor regression, with initial weight loss in mice, which is related to the mode of action of TCB and its induced cytokine release.
Combined with Glofitamab (0.15 mg/kg) led to subsequent recovery of mice without additional weight loss suggestive of tumor progression, indicated potent antitumor activity.
-
Animal Model:OCI-Ly18 tumor-bearing humanized NSG mice[1]
-
Dosage:1 mg/kg
-
Administration:i.v. three times combined injection
-
Result:Combined with Glofitamab (1 mg/kg) increased intratumoral CD8+ and CD4+ T-cell counts.
Combined with Glofitamab (1 mg/kg) led to a marked increase in IFNγ pathway genes, followed by significantly increased cytotoxic T-cell and decreased B-cell signatures.
Combined with Glofitamab (1 mg/kg) and CD19-4-1BBL (1 mg/kg) prolonged the anti-tumor response in vivo and achieving long-term tumor control.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Molecular Weight 145.98 kDa
-
Color Colorless to light yellow
-
SMILES
[RG-6333]
-
Synonyms
RO7443904
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz